| NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease 2023 · NR · Adults aged 35 to under 100 with idiopathic Parkinson’s disease and Hoehn and Yahr score below 4; ages in the enrolled group ranged from 52 to 78 years | 3 g | 4 weeks | 10 |
| Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial 2025 · NR treatment phase · Adults with Werner syndrome; mean age 47 years, 44.4% male | 1 g | 26 weeks | 6 |
| Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial 2024 · NR alone · Adults with peripheral artery disease; mean age 73.21 years in this arm; men and women | 500 mg | 26 weeks | 28 |
| Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease 2023 · NR · Adults aged 30–79 with chronic kidney disease (eGFR below 60 mL/min/1.73 m²) and 6-minute walking distance below 550 m | 1 g | 6 weeks | 25 |
| A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment 2024 · NR group · Older adults with mild cognitive impairment | 1 g | 10 weeks | — |
| Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 2021 · CMA group, phase 3 · Adults aged 18–66 with PCR-confirmed mild-to-moderate COVID-19 who did not require hospitalization | 2 g | 2 weeks | 229 |
| Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 2021 · CMA group, phase 2 · Adults aged 19–66 with PCR-confirmed mild-to-moderate COVID-19 who did not require hospitalization | 2 g | 2 weeks | 71 |
| Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial 2024 · NR + resveratrol · Adults with peripheral artery disease; mean age 70.73 years in this arm; men and women | 500 mg | 26 weeks | 33 |
| Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial 2025 · NR · Sedentary adults aged 55 years and older with hypertension | 500 mg | 6 weeks | 19 |
| Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial 2025 · NR + Ex · Sedentary adults aged 55 years and older with hypertension | 500 mg | 6 weeks | 17 |
| Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults 2018 · NR (nicotinamide riboside) condition · Healthy men and postmenopausal women aged 55–79 years | 1 g | 6 weeks | 30 |
| Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin 2023 · Nicotinamide riboside · Healthy adults, 65 ± 7 years old; 11 men and 11 women | 1 g | 6 weeks | 22 |
| The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans 2026 · NR · Healthy adults aged 18–50 years, male and female | 1 g | 2 weeks | 17 |
| Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial 2024 · NR group (lung-healthy controls) · Lung-healthy adults aged about 60 years or older, never-smokers with no history of lung disease | 500 mg | 6 weeks | 10 |
| The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease 2022 · NR · Newly diagnosed, treatment-naive patients with Parkinson's disease | 1 g | 30 days | — |
| Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults 2019 · 100 mg NIAGEN · Men and non-pregnant, non-breastfeeding women aged 40–60 with BMI 25–30 who were otherwise healthy and overweight | 100 mg | 8 weeks | 35 |
| Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults 2019 · 300 mg NIAGEN · Men and non-pregnant, non-breastfeeding women aged 40–60 with BMI 25–30 who were otherwise healthy and overweight | 300 mg | 8 weeks | 35 |
| Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults 2019 · 1000 mg NIAGEN · Men and non-pregnant, non-breastfeeding women aged 40–60 with BMI 25–30 who were otherwise healthy and overweight | 1 g | 8 weeks | 35 |
| Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial 2024 · NR group (patients with COPD) · Adults aged 60 years or older with non-eosinophilic COPD who were former smokers | 500 mg | 6 weeks | 20 |
| Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans 2020 · NR supplementation · Men and postmenopausal women aged 45–65 with overweight or obesity (BMI 27–35), without active diseases | 1 g | 6 weeks | 13 |
| Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD(+) Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures 2019 · NR · Men aged 70–80 years, otherwise healthy and marginally overweight | 1 g | 3 weeks | 12 |
| Nicotinamide riboside with pterostilbene (NRPT) increases NAD(+) in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI 2020 · NRPT 250/50 mg (Step 1) · Hospitalized adults aged 18 years or older with acute kidney injury | 500 mg | 2 days | 5 |
| Nicotinamide riboside with pterostilbene (NRPT) increases NAD(+) in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI 2020 · NRPT 500/100 mg (Step 2) · Hospitalized adults aged 18 years or older with acute kidney injury | 1 g | 2 days | 5 |
| Nicotinamide riboside with pterostilbene (NRPT) increases NAD(+) in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI 2020 · NRPT 750/150 mg (Step 3) · Hospitalized adults aged 18 years or older with acute kidney injury | 1.5 g | 2 days | 5 |
| Nicotinamide riboside with pterostilbene (NRPT) increases NAD(+) in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI 2020 · NRPT 1000/200 mg (Step 4) · Hospitalized adults aged 18 years or older with acute kidney injury | 2 g | 2 days | 5 |